Tectonic Announces Positive Phase 1 Safety Data for TX2100
Tectonic reported favorable safety and tolerability results for its candidate TX2100 at the APJ receptor, triggering its Fast Track designation and allowing progression into Phase 1b trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed